USD 0.64
(0.0%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 1.53 Billion USD | 8.69% |
2022 | 1.41 Billion USD | 17.86% |
2021 | 1.2 Billion USD | 17.06% |
2020 | 1.02 Billion USD | 7.63% |
2019 | 954.02 Million USD | -12.42% |
2018 | 1.08 Billion USD | 43.08% |
2017 | 761.29 Million USD | 34.33% |
2016 | 566.72 Million USD | -3.29% |
2015 | 585.99 Million USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 1.57 Billion USD | 0.0% |
2024 Q1 | -4.84 Billion USD | -414.96% |
2023 Q3 | - USD | -100.0% |
2023 Q1 | - USD | -100.0% |
2023 Q2 | 1.39 Billion USD | 0.0% |
2023 Q4 | 1.53 Billion USD | 0.0% |
2023 FY | 1.53 Billion USD | 8.69% |
2022 Q4 | 1.41 Billion USD | 0.0% |
2022 FY | 1.41 Billion USD | 17.86% |
2022 Q2 | 1.4 Billion USD | 0.0% |
2021 Q2 | 1.16 Billion USD | 0.0% |
2021 FY | 1.2 Billion USD | 17.06% |
2021 Q4 | 1.2 Billion USD | 0.0% |
2020 FY | 1.02 Billion USD | 7.63% |
2020 Q4 | 1.02 Billion USD | 0.0% |
2020 Q2 | 1.17 Billion USD | 0.0% |
2019 FY | 954.02 Million USD | -12.42% |
2019 Q2 | 962.06 Million USD | 0.0% |
2019 Q4 | 954.02 Million USD | 0.0% |
2018 FY | 1.08 Billion USD | 43.08% |
2017 FY | 761.29 Million USD | 34.33% |
2016 FY | 566.72 Million USD | -3.29% |
2015 FY | 585.99 Million USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
AstraZeneca PLC | 61.86 Billion USD | 97.511% |
Bristol-Myers Squibb Company PFD CONV 2 | 65.67 Billion USD | 97.655% |
Clarus Therapeutics Holdings, Inc. | 67.62 Million USD | -2176.921% |
Novartis AG | 53.19 Billion USD | 97.105% |
PT Kalbe Farma Tbk. | 255.94 Million USD | -501.63% |